Does a mandatory switch from originator adalimumab to biosimilar GP2017 or SB5 lead to increased hospital costs? A DANBIO study of >1,300 patients with inflammatory arthritis

被引：0
|
作者：
Nabi, H. [1 ,2 ,3 ]
Ibsen, R. [4 ]
Ibsen, M. [4 ]
Kjellberg, J. [5 ]
Hetland, M. [1 ,2 ,3 ]
Glintborg, B. [1 ,2 ,3 ]
机构：
[1] Rigshosp, Copenhagen Univ Hosp, DANBIO, Copenhagen, Denmark
[2] Rigshosp, Copenhagen Univ Hosp, Copenhagen Ctr Arthrit Res COPECARE, Ctr Rheumatol & Spine Dis,Ctr Head & Orthoped, Copenhagen, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[4] i2minds, Aarhus, Denmark
[5] Danish Ctr Social Sci, VIVE, Copenhagen, Denmark
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2023年 / 52卷
关键词：
Adalimumab; biosimilars; health-economy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP48
引用
收藏
页码：107 / 108
页数：2
相关论文
共 4 条
  • [1] Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study
    Scrivo, R.
    Castellani, C.
    Mancuso, S.
    Sciarra, G.
    Giardina, F.
    Bevignani, G.
    Ceccarelli, F.
    Spinelli, F. R.
    Alessandri, C.
    Di Franco, M.
    Riccieri, V.
    Priori, R.
    Conti, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (03) : 613 - 619
  • [2] Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting
    Deprez, N.
    De Somer, T.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanderstraeten, E.
    Vandervoort, J.
    Van Heddegem, N.
    Dewint, P.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2022, 85 (04) : 557 - 564
  • [3] Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry
    Tapete, Gherardo
    Bertani, Lorenzo
    Pieraccini, Alberto
    Lynch, Erica Nicola
    Giannotta, Martina
    Morganti, Riccardo
    Biviano, Ivano
    Naldini, Sara
    Mumolo, Maria Gloria
    De Nigris, Francesca
    Calella, Francesca
    Bagnoli, Siro
    Minciotti, Moira
    Maltinti, Simona
    Rentini, Silvia
    Ceccarelli, Linda
    Lionetti, Paolo
    Milla, Monica
    Costa, Francesco
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (01) : 62 - 69
  • [4] Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
    Tursi, Antonio
    Mocci, Giammarco
    Allegretta, Leonardo
    Aragona, Giovanni
    Bianco, Maria Antonia
    Colucci, Raffaele
    Cuomo, Antonio
    Della Valle, Nicola
    Ferronato, Antonio
    Forti, Giacomo
    Gaiani, Federica
    Giorgetti, GianMarco
    Graziani, Maria Giovanna
    Lofano, Katia
    Lorenzetti, Roberto
    Larussa, Tiziana
    Penna, Antonio
    Pica, Roberta
    Pranzo, Giuseppe
    Rodino', Stefano
    Scarcelli, Antonella
    Zampaletta, Costantino
    Bassotti, Gabrio
    Cazzato, Alessia Immacolata
    Chiri, Stefania
    Clemente, Valeria
    Cocco, Andrea
    de' Angelis, Gianluigi
    Donnarumma, Laura
    Faggiani, Roberto
    Graziosi, Camilla
    Le Grazie, Marco
    Luzza, Francesco
    Meucci, Costantino
    Monterubbianesi, Rita
    Pagnini, Cristiano
    Perazzo, Patrizia
    Picchio, Marcello
    Sacco, Rodolfo
    Sebkova, Ladislava
    Serio, Mariaelena
    Napolitano, Daniele
    Pugliese, Daniela
    Scaldaferri, Franco
    Schiavoni, Elisa
    Turchini, Laura
    Armuzzi, Alessandro
    Elisei, Walter
    Maconi, Giovanni
    Papa, Alfredo
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (03) : 376 - 383
1